Amino acids, microbiota-related metabolites, and the risk of incident diabetes among normoglycemic Chinese adults: Findings from the 4C study

[1]  J. Manson,et al.  Host and gut microbial tryptophan metabolism and type 2 diabetes: an integrative analysis of host genetics, diet, gut microbiome and circulating metabolites in cohort studies , 2021, Gut.

[2]  Mei Yu,et al.  Measuring the global, regional, and national burden of type 2 diabetes and the attributable risk factors in all 194 countries , 2021, Journal of diabetes.

[3]  S. Lai,et al.  Association of Serum Bile Acids Profile and Pathway Dysregulation With the Risk of Developing Diabetes Among Normoglycemic Chinese Adults: Findings From the 4C Study , 2020, Diabetes Care.

[4]  E. Tai,et al.  Serum acylcarnitines and amino acids and risk of type 2 diabetes in a multiethnic Asian population , 2020, BMJ open diabetes research & care.

[5]  S. Lai,et al.  Early Life Famine Exposure, Ideal Cardiovascular Health Metrics, and Risk of Incident Diabetes: Findings From the 4C Study , 2020, Diabetes Care.

[6]  R. Gerszten,et al.  Metabolomics and Proteomics in Type 2 Diabetes , 2020, Circulation research.

[7]  B. Cox,et al.  Amino acid and lipid metabolism in post-gestational diabetes and progression to type 2 diabetes: A metabolic profiling study , 2020, PLoS medicine.

[8]  M. Laakso,et al.  Microbiota-Related Metabolites and the Risk of Type 2 Diabetes , 2020, Diabetes Care.

[9]  Hong-Xin Zhang,et al.  2-Aminoadipic acid protects against obesity and diabetes. , 2019, The Journal of endocrinology.

[10]  H. Jang,et al.  2-Aminoadipic acid (2-AAA) as a potential biomarker for insulin resistance in childhood obesity , 2019, Scientific Reports.

[11]  Yu Xu,et al.  High-Coverage Targeted Lipidomics Reveals Novel Serum Lipid Predictors and Lipid Pathway Dysregulation Antecedent to Type 2 Diabetes Onset in Normoglycemic Chinese Adults , 2019, Diabetes Care.

[12]  L. Liang,et al.  High plasma glutamate and low glutamine-to-glutamate ratio are associated with type 2 diabetes: Case-cohort study within the PREDIMED trial. , 2019, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[13]  H. Fan,et al.  Gut microbe–generated metabolite trimethylamine N‐oxide and the risk of diabetes: A systematic review and dose‐response meta‐analysis , 2019, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[14]  S. Lai,et al.  Predictive Value of Fasting Glucose, Postload Glucose, and Hemoglobin A1c on Risk of Diabetes and Complications in Chinese Adults , 2019, Diabetes Care.

[15]  S. Dankel,et al.  Plasma Amino Acids and Incident Type 2 Diabetes in Patients With Coronary Artery Disease , 2019, Diabetes Care.

[16]  L. Pérusse,et al.  Associations Between Dietary Protein Sources, Plasma BCAA and Short-Chain Acylcarnitine Levels in Adults , 2019, Nutrients.

[17]  B. Kahn,et al.  Metabolites as regulators of insulin sensitivity and metabolism , 2018, Nature Reviews Molecular Cell Biology.

[18]  L. Liang,et al.  Association of Tryptophan Metabolites with Incident Type 2 Diabetes in the PREDIMED Trial: A Case-Cohort Study. , 2018, Clinical chemistry.

[19]  L. Liang,et al.  Plasma trimethylamine-N-oxide and related metabolites are associated with type 2 diabetes risk in the Prevención con Dieta Mediterránea (PREDIMED) trial. , 2018, The American journal of clinical nutrition.

[20]  G. Bray,et al.  Gut microbiota metabolites, amino acid metabolites and improvements in insulin sensitivity and glucose metabolism: the POUNDS Lost trial , 2018, Gut.

[21]  Harry Sokol,et al.  Gut Microbiota Regulation of Tryptophan Metabolism in Health and Disease. , 2018, Cell host & microbe.

[22]  L. Liang,et al.  Plasma branched chain/aromatic amino acids, enriched Mediterranean diet and risk of type 2 diabetes: case-cohort study within the PREDIMED Trial , 2018, Diabetologia.

[23]  E. Boerwinkle,et al.  Serum metabolomic profile of incident diabetes , 2018, Diabetologia.

[24]  G. Tell,et al.  Serum Carnitine Metabolites and Incident Type 2 Diabetes Mellitus in Patients With Suspected Stable Angina Pectoris , 2018, The Journal of clinical endocrinology and metabolism.

[25]  Xun Xu,et al.  Analyses of gut microbiota and plasma bile acids enable stratification of patients for antidiabetic treatment , 2017, Nature Communications.

[26]  J. Klánová,et al.  Urinary intermediates of tryptophan as indicators of the gut microbial metabolism. , 2017, Analytica chimica acta.

[27]  F. Hu,et al.  Association between microbiota-dependent metabolite trimethylamine-N-oxide and type 2 diabetes. , 2017, The American journal of clinical nutrition.

[28]  Huijue Jia,et al.  Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention , 2017, Nature Medicine.

[29]  P. Njølstad,et al.  The kynurenine:tryptophan ratio as a predictor of incident type 2 diabetes mellitus in individuals with coronary artery disease , 2017, Diabetologia.

[30]  Tero Aittokallio,et al.  Early metabolic markers identify potential targets for the prevention of type 2 diabetes , 2017, Diabetologia.

[31]  M. Obrenovich,et al.  Targeted Metabolomics Analysis Identifies Intestinal Microbiota-Derived Urinary Biomarkers of Colonization Resistance in Antibiotic-Treated Mice , 2017, Antimicrobial Agents and Chemotherapy.

[32]  M. Zou,et al.  Abnormal kynurenine pathway of tryptophan catabolism in cardiovascular diseases , 2017, Cellular and Molecular Life Sciences.

[33]  Ashutosh Kumar Singh,et al.  Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015 , 2016, The Lancet.

[34]  F. Hu,et al.  Plasma metabolomics identified novel metabolites associated with risk of type 2 diabetes in two prospective cohorts of Chinese adults. , 2016, International journal of epidemiology.

[35]  Y. Bao,et al.  Tryptophan Predicts the Risk for Future Type 2 Diabetes , 2016, PloS one.

[36]  Jian-Min Yuan,et al.  Metabolic signatures and risk of type 2 diabetes in a Chinese population: an untargeted metabolomics study using both LC-MS and GC-MS , 2016, Diabetologia.

[37]  L. Liang,et al.  Early Prediction of Developing Type 2 Diabetes by Plasma Acylcarnitines: A Population-Based Study , 2016, Diabetes Care.

[38]  Mee-Sup Yoon.  The Emerging Role of Branched-Chain Amino Acids in Insulin Resistance and Metabolism , 2016, Nutrients.

[39]  P. Njølstad,et al.  Prospective Associations of Systemic and Urinary Choline Metabolites with Incident Type 2 Diabetes. , 2016, Clinical chemistry.

[40]  Y. Bao,et al.  Branched-chain and aromatic amino acid profiles and diabetes risk in Chinese populations , 2016, Scientific Reports.

[41]  Nicholette D. Palmer,et al.  Metabolomic profile associated with insulin resistance and conversion to diabetes in the Insulin Resistance Atherosclerosis Study. , 2015, The Journal of clinical endocrinology and metabolism.

[42]  Sophie V. Eastwood,et al.  Diabetes risk and amino acid profiles: cross-sectional and prospective analyses of ethnicity, amino acids and diabetes in a South Asian and European cohort from the SABRE (Southall And Brent REvisited) Study , 2015, Diabetologia.

[43]  C. Lynch,et al.  Branched-chain amino acids in metabolic signalling and insulin resistance , 2014, Nature Reviews Endocrinology.

[44]  N. Kaji,et al.  Reduced plasma glucose by asparagine synthetase knockdown in the mouse liver. , 2013, Biological & pharmaceutical bulletin.

[45]  R. Vasan,et al.  2-Aminoadipic acid is a biomarker for diabetes risk. , 2013, The Journal of clinical investigation.

[46]  M. Schulze,et al.  Variation of serum metabolites related to habitual diet: a targeted metabolomic approach in EPIC-Potsdam , 2013, European Journal of Clinical Nutrition.

[47]  A. Peters,et al.  Identification of Serum Metabolites Associated With Risk of Type 2 Diabetes Using a Targeted Metabolomic Approach , 2013, Diabetes.

[48]  Susan Cheng,et al.  Metabolite Profiling Identifies Pathways Associated With Metabolic Risk in Humans , 2012, Circulation.

[49]  V. Mootha,et al.  Metabolite profiles and the risk of developing diabetes , 2011, Nature Medicine.

[50]  D. Mozaffarian,et al.  Defining and Setting National Goals for Cardiovascular Health Promotion and Disease Reduction: The American Heart Association's Strategic Impact Goal Through 2020 and Beyond , 2010, Circulation.

[51]  J. Towbin,et al.  “ Defining and Setting National Goals for Cardiovascular Health Promotion and Disease Reduction : The American Heart Association ’ s Strategic Impact , 2016 .